Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3347297
Max Phase: Preclinical
Molecular Formula: C211H330N52O65
Molecular Weight: 4635.26
Molecule Type: Protein
Associated Items:
ID: ALA3347297
Max Phase: Preclinical
Molecular Formula: C211H330N52O65
Molecular Weight: 4635.26
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(C)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O
Standard InChI: InChI=1S/C211H330N52O65/c1-13-111(8)173(260-198(315)135(56-30-40-96-220)234-180(297)130(51-25-35-91-215)237-205(322)157(105-172(292)293)259-203(320)155(103-119-108-228-126-47-21-18-44-123(119)126)257-197(314)147(72-85-169(286)287)243-189(306)141(66-79-163(274)275)246-201(318)153(229-115(12)265)101-117-106-226-124-45-19-16-42-121(117)124)209(326)252-149(74-87-171(290)291)193(310)245-146(71-84-168(284)285)196(313)255-152(100-116-58-60-120(266)61-59-116)207(324)263-176(114(11)264)211(328)250-134(55-29-39-95-219)182(299)235-136(57-31-41-97-221)199(316)261-174(112(9)14-2)210(327)251-148(73-86-170(288)289)192(309)244-145(70-83-167(282)283)195(312)254-151(99-110(6)7)206(323)262-175(113(10)15-3)208(325)249-133(54-28-38-94-218)181(298)232-131(52-26-36-92-216)183(300)256-154(102-118-107-227-125-46-20-17-43-122(118)125)202(319)247-142(67-80-164(276)277)190(307)240-139(64-77-161(270)271)187(304)239-138(63-76-159(223)268)186(303)238-137(62-75-158(222)267)185(302)233-129(50-24-34-90-214)179(296)231-132(53-27-37-93-217)184(301)258-156(104-160(224)269)204(321)248-143(68-81-165(278)279)191(308)241-140(65-78-162(272)273)188(305)242-144(69-82-166(280)281)194(311)253-150(98-109(4)5)200(317)236-128(49-23-33-89-213)178(295)230-127(177(225)294)48-22-32-88-212/h16-21,42-47,58-61,106-114,127-157,173-176,226-228,264,266H,13-15,22-41,48-57,62-105,212-221H2,1-12H3,(H2,222,267)(H2,223,268)(H2,224,269)(H2,225,294)(H,229,265)(H,230,295)(H,231,296)(H,232,298)(H,233,302)(H,234,297)(H,235,299)(H,236,317)(H,237,322)(H,238,303)(H,239,304)(H,240,307)(H,241,308)(H,242,305)(H,243,306)(H,244,309)(H,245,310)(H,246,318)(H,247,319)(H,248,321)(H,249,325)(H,250,328)(H,251,327)(H,252,326)(H,253,311)(H,254,312)(H,255,313)(H,256,300)(H,257,314)(H,258,301)(H,259,320)(H,260,315)(H,261,316)(H,262,323)(H,263,324)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)/t111-,112-,113-,114+,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,173-,174-,175-,176-/m0/s1
Standard InChI Key: DWXUWDOCVSACSG-GEBWNPKESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 4635.26 | Molecular Weight (Monoisotopic): 4632.4116 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Oishi S, Watanabe K, Ito S, Tanaka M, Nishikawa H, Ohno H, Shimane K, Izumi K, Sakagami Y, Kodama EN, Matsuoka M, Asai A, Fujii N. (2010) Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants, 1 (4): [10.1039/C0MD00091D] |
Source(1):